These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 11448571)

  • 1. A randomized controlled trial comparing effects of a low-energy diet with n-3 polyunsaturated fatty acid supplementation in patients with non-alcoholic fatty liver disease.
    Shojasaadat F; Ayremlou P; Hashemi A; Mehdizadeh A; Zarrin R
    J Res Med Sci; 2019; 24():21. PubMed ID: 31007691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Follow up (Telenursing) on Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial.
    Fard SJ; Ghodsbin F; Kaviani MJ; Jahanbin I; Bagheri Z
    Int J Community Based Nurs Midwifery; 2016 Jul; 4(3):239-46. PubMed ID: 27382590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.
    Arab JP; Candia R; Zapata R; Muñoz C; Arancibia JP; Poniachik J; Soza A; Fuster F; Brahm J; Sanhueza E; Contreras J; Cuellar MC; Arrese M; Riquelme A
    World J Gastroenterol; 2014 Sep; 20(34):12182-201. PubMed ID: 25232252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of nonalcoholic steatohepatitis with vitamins E and C: a pilot study.
    Kawanaka M; Nishino K; Nakamura J; Suehiro M; Goto D; Urata N; Oka T; Kawamoto H; Nakamura H; Yodoi J; Hino K; Yamada G
    Hepat Med; 2013; 5():11-6. PubMed ID: 24695939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lifestyle Modification through Dietary Intervention: Health Promotion of Patients with Non-Alcoholic Fatty Liver Disease.
    Arefhosseini SR; Ebrahimi-Mameghani M; Farsad Naeimi A; Khoshbaten M; Rashid J
    Health Promot Perspect; 2011; 1(2):147-54. PubMed ID: 24688911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non alcoholic fatty liver disease in southern Iran: a population based study.
    Lankarani KB; Ghaffarpasand F; Mahmoodi M; Lotfi M; Zamiri N; Heydari ST; Fallahzadeh MK; Maharlouei N; Babaeinejad M; Mehravar S; Geramizadeh B
    Hepat Mon; 2013 May; 13(5):e9248. PubMed ID: 23922564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).
    Lomonaco R; Chen J; Cusi K
    Ther Adv Endocrinol Metab; 2011 Oct; 2(5):211-25. PubMed ID: 23148186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of clinical condition and mycophenolate mofetil on plasma retinol, α-tocopherol and β-carotene in renal transplant recipients.
    Kamińnska J; Sobiak J; Głyda M; Duda G; Nogala-Kałucka M; Siger A; Chrzanowska M
    Arch Med Sci; 2012 May; 8(2):256-62. PubMed ID: 22661998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment options for nonalcoholic fatty liver disease.
    Lam B; Younossi ZM
    Therap Adv Gastroenterol; 2010 Mar; 3(2):121-37. PubMed ID: 21180596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits.
    Ogawa T; Fujii H; Yoshizato K; Kawada N
    Am J Pathol; 2010 Jul; 177(1):153-65. PubMed ID: 20489159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia.
    Zhu FS; Liu S; Chen XM; Huang ZG; Zhang DW
    World J Gastroenterol; 2008 Nov; 14(41):6395-400. PubMed ID: 19009658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current treatments in nonalcoholic steatohepatitis.
    Torres DM; Harrison SA
    Curr Treat Options Gastroenterol; 2007 Dec; 10(6):425-34. PubMed ID: 18221603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing nonalcoholic fatty liver disease: recommendations for family physicians.
    Grattagliano I; Portincasa P; Palmieri VO; Palasciano G
    Can Fam Physician; 2007 May; 53(5):857-63. PubMed ID: 17872748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of non-alcoholic fatty liver disease.
    Adams LA; Angulo P
    Postgrad Med J; 2006 May; 82(967):315-22. PubMed ID: 16679470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ detection of oxidized n-3 polyunsaturated fatty acids in chronic hepatitis C: correlation with hepatic steatosis.
    Kitase A; Hino K; Furutani T; Okuda M; Gondo T; Hidaka I; Hara Y; Yamaguchi Y; Okita K
    J Gastroenterol; 2005 Jun; 40(6):617-24. PubMed ID: 16007396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Nonalcoholic Fatty Liver Disease.
    Liangpunsakul S; Chalasani N
    Curr Treat Options Gastroenterol; 2003 Dec; 6(6):455-463. PubMed ID: 14585234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Options in Nonalcoholic Fatty Liver Disease.
    Tokar JL; Berg CL
    Curr Treat Options Gastroenterol; 2002 Dec; 5(6):425-436. PubMed ID: 12408779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a moderately energy-restricted diet on obese patients with fatty liver.
    Okita M; Hayashi M; Sasagawa T; Takagi K; Suzuki K; Kinoyama S; Ito T; Yamada G
    Nutrition; 2001; 17(7-8):542-7. PubMed ID: 11448571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinol and alpha-tocopherol in morbid obesity and nonalcoholic fatty liver disease.
    Botella-Carretero JI; Balsa JA; Vázquez C; Peromingo R; Díaz-Enriquez M; Escobar-Morreale HF
    Obes Surg; 2010 Jan; 20(1):69-76. PubMed ID: 18830789
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.